Elucid
Elucid is a Boston-based medical technology company using validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Their platform offers ground-truth validated, non-invasive imaging analysis to quantify plaque characteristics, assess risk, and support personalized treatment plans, aiming to prevent heart attacks and strokes through advanced diagnostics and AI-driven insights.
Industries
Nr. of Employees
medium (51-250)
Elucid
Products
CTA-based plaque analysis software (histology-validated)
Software that analyzes CT angiography to quantify plaque morphology and tissue types (lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage) and produces clinician-facing reports and 3D visualizations. Documented validation against histopathology and peer-reviewed publications support analytic performance.
FFRct estimation software (CTA-based)
Software module that derives fractional flow reserve estimates from CTA-derived plaque and vessel metrics to assess lesion-specific ischemia without invasive catheterization.
Research edition with extended biomarkers (research-only features)
Extended software edition exposing additional research biomarkers (e.g., detailed intraplaque hemorrhage and fibrous cap/perivascular adipose tissue measures) for investigational use and study applications.
CTA-based plaque analysis software (histology-validated)
Software that analyzes CT angiography to quantify plaque morphology and tissue types (lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage) and produces clinician-facing reports and 3D visualizations. Documented validation against histopathology and peer-reviewed publications support analytic performance.
FFRct estimation software (CTA-based)
Software module that derives fractional flow reserve estimates from CTA-derived plaque and vessel metrics to assess lesion-specific ischemia without invasive catheterization.
Research edition with extended biomarkers (research-only features)
Extended software edition exposing additional research biomarkers (e.g., detailed intraplaque hemorrhage and fibrous cap/perivascular adipose tissue measures) for investigational use and study applications.
Services
Analytical service that processes CTA to quantify plaque composition and provide lesion- and vessel-level reports validated against histopathology.
Service to estimate lesion-specific fractional flow reserve from CTA-derived plaque and vessel measurements as a non-invasive ischemia assessment.
Support for investigator-initiated studies, registries, and industry-sponsored trials to provide imaging-derived endpoints, stratification, and longitudinal analysis for therapeutic evaluation.
Analytical service that processes CTA to quantify plaque composition and provide lesion- and vessel-level reports validated against histopathology.
Service to estimate lesion-specific fractional flow reserve from CTA-derived plaque and vessel measurements as a non-invasive ischemia assessment.
Support for investigator-initiated studies, registries, and industry-sponsored trials to provide imaging-derived endpoints, stratification, and longitudinal analysis for therapeutic evaluation.
Expertise Areas
- Cardiovascular computed tomography image analysis
- Quantitative imaging biomarkers and histology correlation
- Non-invasive ischemia assessment (FFRct)
- AI and machine learning for medical image tissue classification
Key Technologies
- Computed tomography angiography (CTA) analysis
- Machine learning / neural networks for image tissue classification
- FFRct estimation from imaging
- Virtual transcriptomics (imaging-derived RNA expression)
News & Updates
Jul 7, 2025 | Cardiac CT Expert to Advance Research and Commercialization of Company’s PlaqueIQ™ Image Analysis Software.
Mar 3, 2025 | Elucid has added several senior members to its clinical and commercial teams.
Nov 4, 2024 | Decision makes cardiovascular imaging technologies more viable for providers.
FDA 510(k) Clearance for PlaqueIQ™
Received FDA 510(k) clearance for its ground-truth validated plaque analysis software.
Series B Funding of $27 Million
Closed a $27 million Series B financing round to expand commercialization.
FDA and CE Mark Approval for PlaqueIQ™
First FDA-cleared and CE-marked software for non-invasive plaque quantification.
Jul 7, 2025 | Cardiac CT Expert to Advance Research and Commercialization of Company’s PlaqueIQ™ Image Analysis Software.
Mar 3, 2025 | Elucid has added several senior members to its clinical and commercial teams.
Nov 4, 2024 | Decision makes cardiovascular imaging technologies more viable for providers.
FDA 510(k) Clearance for PlaqueIQ™
Received FDA 510(k) clearance for its ground-truth validated plaque analysis software.
Series B Funding of $27 Million
Closed a $27 million Series B financing round to expand commercialization.
FDA and CE Mark Approval for PlaqueIQ™
First FDA-cleared and CE-marked software for non-invasive plaque quantification.